Omicron Delivers Blow to Boston Sci’s Guidance

Image courtesy of Kristoffer Tripplaar / Alamy Stock Photo


The Marlborough, MA-based company fell below consensus for 1Q22 guidance and full-year 2022 guidance.

Omar Ford | Feb 03, 2022

Boston Scientific is the latest company to have its earnings impacted by staffing shortages and the disruptions caused by the Omicron variant. The Marlborough, MA-based company did not meet consensus for 1Q22 guidance and full year 2022 guidance.

The company said its 1Q22 adjusted earnings per share to come between 38 cents and 40 cents with EPS between $1.73 and $1.79. EPS consensus of 41 cents and full-year EPS of $1.87.

“Omicron has had an impact in December and the first part here of Q1,” Boston Scientific Chairman and CEO Mike Mahoney said according to a transcript from the Motely Fool. “But as we look at the rest of the year, the goal is and the belief is that there will be less impact in '22 than there was in '21. So, we see a brighter future, particularly as you get to that second half, as the macro environment gets a little bit better, COVID waned even more than it had in '21, and that gives us reason for optimism as we go through the year.”

Marie Thibault, an analyst with BTIG, said the impact of COVID did not come as a surprise.

“We anticipated initial guidance might account for continued COVID and staffing shortage headwinds in the early part of the year,” Thibault wrote in research. “The full-year revenue guidance range continues to point to the +6-8% growth that management has set as a target for 2022 to 2024 CAGR.”

Convatec to acquire Triad for up to $450M to break into Wound Biologics

Deeside, UK, and Memphis, TN, January 28, 2022 (ConvaTec Group PLC) — ConvaTec Group Plc (CTEC.LN), a global medical solutions company focused on the management of chronic conditions, is pleased to announce that it has entered into a definitive agreement to acquire Triad Life Sciences Inc(1) (‘Triad’), a US-focused medical device company that develops biologically-derived innovative products to address unmet clinical needs in surgical wounds, chronic wounds and burns.


 Read More

 Read More  Smith+Nephew acquires Engage for up to $135M

London, UK, January 19, 2022 (PRNewswire) — Smith+Nephew (LSE: SN,NYSE: SNN), the global medical technology business, announces the acquisition of Engage Surgical, owner of the only cementless unicompartmental (partial) knee system commercially available in the US.


Additional Articles

Aging population creates a positive future for the Medical Devices Industry. 

The positive future and impact of Robotics Surgery